TriSalus Life Sciences, Inc. Warrant (TLSIW) Stock Price
TLSIWStock
$0.88
Market Cap—
P/E—
PEG Ratio—
Div yield—
Beta1.79
TLSIW Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-7.25%
Price vs S&P 500 (4W)8.67%
VGM Score27.87
Industry Peers — Surgical & Medical Instruments(140)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
TLSIWTriSalus Life Sciences, Inc. Warrant | — | — | D | $0.88 |
| SYKStryker Corporation | C | B | C | $330.69 |
| MMM3M Company | C | D | C | $174.34 |
| BSXBoston Scientific Corp. | C | B | D | $46.84 |
| BDXBecton, Dickinson and Co. | B | D | B | $189.52 |
| MDLNMedline Inc. Class A common stock | C | D | C | $35.28 |
| RMDResMed Inc. | C | B | B | $240.33 |
| DXCMDexCom, Inc. | D | B | B | $90.82 |
| WSTWest Pharmaceutical Services, Inc. | D | C | B | $337.47 |
| SOLVSolventum Corporation | C | C | B | $91.12 |
| BAXBaxter International Inc. | B | D | B | $26.13 |
About TriSalus Life Sciences, Inc. Warrant
TriSalus Life Sciences develops drug delivery systems and immune-oncology therapeutics targeting difficult-to-treat liver and pancreatic cancers. The company markets PEDD (Pressure Enabled Drug Delivery) infusion systems, including its latest TriNav device with SmartValve technology, which are in clinical use today. It is also advancing nelitolimod (SD-101), an investigational agent designed to enhance immune response against hepatocellular carcinoma, pancreatic cancer, and other liver tumors.